SIHUAN PHARM (00460) announced its interim results for 2025, with revenue reaching RMB1.146 billion (same currency hereinafter), representing a year-on-year increase of 20.69%. Profit attributable to shareholders amounted to RMB103 million, compared to a loss of RMB33.424 million in the same period last year, achieving a turnaround from loss to profit. Basic earnings per share stood at 1.11 cents, and the company proposed an interim cash dividend of 0.99 cents per share.
According to the announcement, the revenue change was driven by the aesthetic medicine business, which generated approximately RMB585 million in revenue (compared to RMB323 million in the same period of 2024), representing an increase of approximately 81.3% year-on-year. This growth was primarily attributed to the group's aesthetic medicine platform Meiyan Space strengthening strategic partnerships with multiple aesthetic medicine institutions and successfully promoting the upgraded version 3.0 of its marketing strategy during the period. The products received high market recognition, significantly driving aesthetic medicine sales revenue growth.
Innovation research and development along with improving the product matrix serve as the core engine of Meiyan Space's competitiveness. Currently, Meiyan Space has successfully established five major R&D platforms, focusing respectively on international innovative materials research, regenerative materials product development, HA product development, biological macromolecule product development, and composite innovative materials development. A professional and efficient aesthetic medicine R&D team of over 80 people rapidly advances product development and registration progress, creating more than 60 aesthetic medicine product pipelines covering basic categories of minimally invasive aesthetics including injections, photoelectric equipment, weight-loss medications, and skincare products.
During the period, Meiyan Space successfully achieved further breakthroughs in the regenerative field, with two independently developed regenerative injection products - Injectable Polycaprolactone Microsphere Facial Filler (Maiden Injection) and Polylactic Acid Facial Filler (Youth Injection) - both receiving marketing approval.